SlideShare a Scribd company logo
Development of novel chemically-defined media for
CHO cell applications

Dr. Dipl-Ing. Jörg von Hagen
Head of Process Development & Launch
Management Merck Millipore, Darmstadt, Germany

Cell Culture World Congress, Munich 2013
Presentation Outline
1
2

Lot to Lot Consistency

3

Platform Consistency

4

Media Performance Prediction

5

Powder handling improvements

6

Solubility Toolbox for high performing media

7

2

CHO Cell Media & Feed – Performance evaluation

Perspectives

2
A Comparison of IgG Production in CVC-200 and
Two Competitor Media and Feed Supplements.
3.5
3
80

2.5

60

2
1.5

40

IgG Titer (g/L)

Cell Viability (% Viable Cells)

100

1
20
0.5
0

0
0

3

4

5

6

7

8

9

10

11

12

13

14

Elapsed Time (Day)
Competitor A

Competitor B

Cellvento CHO-200

Competitor A

Competitor B

Cellvento CHO-200

IgG Production in Cellvento CHO-200 was 2-3 fold higher than two competitor
products over a 14 day fed batch culture.
3
A Comparison of Cell Growth in CVC-200 and Two
Competitor Media and Feed Supplements
Cell Growth (VCD) - Competitive Evaluation in Fed Batch

14.00

VCD (10e6 c/ml)

12.00
10.00
8.00
6.00
4.00
2.00
0.00
0.0

2.0

4.0

6.0

8.0

10.0

12.0

14.0

Elapsed Time (Day)
Competitor A

Competitor B

Cellvento CHO-200

Cell growth in Cellvento CHO-200 achieved above 1x107 cells /mL in a 14 day
fed batch culture.
4
Presentation Outline
1
2

Lot to Lot Consistency

3

Platform Consistency

4

Media Performance Prediction

5

Powder handling improvements

6

Solubility Toolbox for high performing media

7

5

CHO Cell Media & Feed – Performance evaluation

Perspectives

5
Integral Viable Cell Density
(10e6 cell day/ml)

Comparison of Average Cell Growth in Batch Culture

25.00
20.00
Lot 006_1

15.00

Lot 006_2
Lot 006_3

10.00
5.00
0.00
3

4

5

6

Elapsed Time (Days)

Cell growth in Cellvento CHO-200 was consistent in batch culture across three
lots of media
6
Comparison of Cell Growth in Fed Batch Culture
Three Lots of Feed tested
18,0
16,0

Viable Cell Density (10e6 c/ml)

14,0
12,0

Feed Lot 007_1

10,0

Feed Lot 007_2

8,0

Feed Lot 007_3

6,0
4,0

2,0
0,0
0

5

10

15

Elapsed Time (Day)

Cell growth in Cellvento CHO-200 was consistent in fed batch culture across
three lots of feed
7
Comparison of IgG Production in Fed Batch Culture

Comparison of Volumetric Titers Across Three Lots of Feed
2.0
1.8
1.6
1.4
IgG (g/L)

1.2
Feed Lot 007_1

1.0
Feed Lot 007_2

0.8

Feed Lot 007_3

0.6
0.4
0.2
0.0
7

10
Sample Day

IgG production in Cellvento CHO-200 was consistent in fed batch culture
across three lots of feed
8
PSD Media

9
PSD Feed

10
Reproducibility amino acid content
Cellvento CHO 200 media

Amino acid concentration (in % of the
theoretical value)

120
100
80

Batch 1
Batch 2

60

Batch 3
40
20
0
His

11

Asn

Ser

Arg

Presentation title in footer | 00 Month 0000

Gly

Asp

Glu

Thr

Ala

Pro

Lys

Tyr

Met

Val

Ile

Leu

Phe
Presentation Outline
1
2

Lot to Lot Consistency

3

Platform Consistency

4

Media Performance Prediction

5

Powder handling improvements

6

Solubility Toolbox for high performing media

7

12

CHO Cell Media & Feed – Performance evaluation

Perspectives

12
A Comparison of Cell Growth in Spin Tubes and 3L
Benchtop Bioreactors

16

Viable Cell Density (10e6 c/ml)

14
12
10
3L Cellready Bioreactor

8

50 ml Spin Tubes

6
4
2
0
0

2

4

6

8

10

12

14

Elapsed Time (Day)

Similar growth performance was achieved with Cellvento CHO-200 in spin tubes
and benchtop bioreactors over a 14 day fed batch culture.
13
A Comparison of IgG Production in Spin Tubes and
3L Benchtop Bioreactors

1,8
1,6
1,4

IgG (g/L)

1,2
50 ml Spin Tubes

1

3L Cellready
Bioreactor

0,8
0,6
0,4
0,2
0
7

10
Sample Day

IgG titers averaged 1.5 g/L after 10 days of fed bath culture using
Cellvento CHO-200 in spin tubes and benchtop bioreactors.
14
Presentation Outline
1
2

Lot to Lot Consistency

3

Platform Consistency

4

Media Performance Prediction

5

Powder handling improvements

6

Solubility Toolbox for high performing media

7

15

CHO Cell Media & Feed – Performance evaluation

Perspectives

15
NIR - Near Infrared Spectroscopy
A fingerprint method for media performance prediction

medium
performance

high performance
low performance

PCA-Possibility for clustering good and poor performing media batches
Measurement conditions
Integrating sphere, PbS-detector, diffuse reflexion
Instrument: BrukerVector 22/N
Number of scans: 16, Resolution: 8 cm-1, Measurement Range: 12000 – 4000 cm-1
Principle component analysis (PCA)
Correlation of cellular performance and NIR analysis
Supplier C-1
Supplier S
Supplier C-2
Supplier B

Supplier C-3
EMD Millipore

Supplier A

PCA of DMEM-F12. Analysis by NIR-Spectroscopy (Bruker, Vektor MPA)
Quality Testing of Media …
…depends on the appropriate test system
25

cumulative PDL

20

Mill Tech 1-1
15

Mill Tech 1-2
Mill Tech 1-3
Mill Tech 2-1

10

Mill Tech 2-2
Mill Tech 2-3

5

0
0 days

3 days

5 days

7 days

10 days

12 days

14 days

17 days

Impact of the milling technology on CHO-S cells grown in chemically defined media.
No significant differences are observed in the basic cell culture assay analyzing the
cumulative population doubling levels (PDL) using different produced mammalian
cell culture media.
Sensitive Cell Culture Assays
… underline differences in cell culture media performance
70

60

plating efficacy (%)

50

40

30

20

10

0
Supplier A

Mill Tech 1-1

Mill Tech 1-2

Mill Tech 1-3

Mill Tech 2-1

Mill Tech 2-2

Mill Tech 2-3

Impact of the milling technology on CHO-S plating efficacy in chemically defined media.
CHO-S cells were diluted in the corresponding media and analyzed after 2 weeks on
plating efficacy.
Impact of Processing Technologies
Impact of the milling technology on mAb titer
140
130

Titer ( % to internal reference)

120
110
100
90
80
70
60
50
40
30
20
10
0
Supplier A

Mill Tech 2

The media were tested in the production of a monoclonal antibody.
Titer was measured by Surface Plasmon Resonance Spectroscopy.
Red line indicates the minimum achievable titer according to the specifications.
Milling Process Impact on final NBE Attribute
Impact of the milling technology on critical antibody attributes
35

Critical Peptides (%)

30

25

20

15

10

5

0
Supplier A

Mill Tech 2

Final molecules after capture were analyzed by HPLC to determine the amount (%) of
critical peptides that are known to be correlated with lower half life of the drug substance
in patient serum samples. The amounts are directly linked with the raw material quality
and the production process.
Red line indicates the max. value given by the authorities. Dotted red line represents the internal specification limit.
Range between dotted blue lines show the target space for good media performance.
Presentation Outline
1
2

Lot to Lot Consistency

3

Platform Consistency

4

Media Performance Prediction

5

Powder handling improvements

6

Solubility Toolbox for high performing media

7

22

CHO Cell Media & Feed – Performance evaluation

Perspectives

22
Humidity and impact on powder flowability
CDM II
DMEM-F12
CDM I

After opening the package the first time the CDM II powder is clumpy. The DMEMF12 and CDM I media are opened several times and are free flowing powders.
CDM II: particle size distribution

CDM II particle size analysis is
technically not feasible by air-jet
sieving. After 3 min all material
gets like chewing gum, whereas
for CDM I and DMEM-F12
particle size distribution analysis
went without clumping.
CDM composition comparison
The CDM I and II composition have the following critical hygroscopic
ingredients:

– Calcium Chloride 2H2O
– Choline Chloride

– Ferric Nitrate 9 H2O
– Ferrous Sulfate 7 H2O

– Sodium phosphate, monobasic, monohydrate
 the above listed ingredients are present with a concentration in sum of 1.5% in
the CDM I and 9.7% in the CDM II formulation.

 6.3-fold enrichment of hygroscopic compounds resulted in a final H 2O titer
of 4.05% measured by Karl Fischer Titration in the CDM II powder

(compared to 1.05 to 1.2 in DMEM-F12 and CDM I.)
Humidity effects solubility of DMEM F12

2 – 8 °C

4 fold accelerated (5min real)

6 h / 28 °C / 90 % rH.
17° increase in avalanche angle after
DMEM F12 exposure to 90% rH

DMEM F12 before and after flowability measurement (3h/25°C at 90% rH)
DMEM-F12 compacted

R = Rosa = pinkish

uncompressed 20KN

30KN

40KN

50KN

60KN
DMEM-F12 compacted
uncompressed

20KN

30KN

1 mm

1 mm

1 mm

1 mm

1 mm

1 mm

40KN

50KN

60KN

1-3 mm particle sizes
Solubility of DMEM F12 powder vs. granules
Filterability of Powder vs. Granules of DMEM F12
Compaction Filter
Medium
(kN)
Family

Filter
Name

Filter Pore
Size
(µm)

Vmax
(L/m2)

Amin
(m2)

0
0

SHR

0,1

9 305

0,28

Express

SHR-2L

0.5/0.1

20 555

0,29

30
30

Express

SHR

0.1

11 221

0,29

Express

SHR-2L

0.5/0.1

37 911

0,31

60

Express

SHR

0.1

10 596

0,30

60

DMEM
F-12

Express

Express

SHR-2L

0.5/0.1

44 219

0,31

The Amin represents the minimal surface of membrane needed to process 500L
within the defined time.
Presentation Outline
1
2

Lot to Lot Consistency

3

Platform Consistency

4

Media Performance Prediction

5

Powder handling improvements

6

Solubility Toolbox for high performing media

7

32

CHO Cell Media & Feed – Performance evaluation

Perspectives

32
Tyrosine solubility in feed with >110 g/L
amino acid & vitamin load

L-Tyr

1

L-Tyr 2Na

1

mod L-Tyr I

mod L-Tyr II

50

g/L @ pH 7.0 +/- 0.2

70
4,5mM 2Na-Tyr

CHO-S growth profile comparing L-Tyrosine
Disodium salt vs. modified Tyrosine 4,5mM 2Na-P-Tyr
Medium
200

180

160

Lebenszellzahl [vc/ml] x10^5

VCD (x105 vc/mL)

0
1
1
1
1
1
1
1

1
2
3
4
5
6
7

1
29,6333333
33,2
11,5333333
24,15
24,6666667
19
16,4666667

4
753,033333
681,6
61,0666667
528,6
462,9
85,2666667
116,266667

5
1264,53333
1218,13333
73,0666667
1318,4
1197,26667
157,4
135,9

6
1541,13333
1470,4
64,8999992
1409,82503
1441,11333
266,206664
117,206667

7
8
988,936665
333,58
1108,24002
548,75
46,4400007 63,1033333
1393,7
1324,422
1578,69001 1502,80333
375,935004 415,776667
78,376667
71,34

0
1,92
2,07
2,49
4,5mM 2Na-Tyr
0,29546573

140

4.5 mM L-Tyr 2Na
4,5mM 2Na-Tyr

120

100
4,5mM 2Na-P-Tyr

4.5 mM mod L-Tyr
4,5mM 2Na-P-Tyr II

80

60

9.0 mM mod L-Tyr
9mM 2Na-P-Tyr II

40

18,33
0,31

20
9mM 2Na-P-Tyr
0
1

3

9

5

7

time (days)
time

11
9

11
Presentation Outline
1
2

Lot to Lot Consistency

3

Platform Consistency

4

Media Performance Prediction

5

Powder handling improvements

6

Solubility Toolbox for high performing media

7

35

CHO Cell Media & Feed – Performance evaluation

Perspectives

35
Perspectives in media preparation
• The raw material quality is key for optimal
media performance on cellular level
• Raw material selection
• Raw material pre-processing
• Novel raw material development
• Supply chain
• The production process is directly linked with
batch to batch consistency and cellular
performance

• Milling process
• Mixing process
• Packaging
• The combination of raw materials and the
production process is mandatory for excellent dry
powder media performance

Raw
material
quality

Production
process

Cellular
performance

More Related Content

PPTX
PPT
Cell cloning, animal cell culture
PPTX
Insect cell culture
PDF
Cell Line Development: Reducing timelines and increasing titres
PPT
Tetramers-ppt
PDF
Part 1 - Weighing & Weights 2015-16
PPT
Protein protein interaction
Cell cloning, animal cell culture
Insect cell culture
Cell Line Development: Reducing timelines and increasing titres
Tetramers-ppt
Part 1 - Weighing & Weights 2015-16
Protein protein interaction

What's hot (20)

PPTX
Protein array, types and application
PPTX
Developing a new probiotic
PPTX
Fodder yeast production
PPTX
milk procurement
PPTX
6 how do we culture cells in the laboratory lecture 6
PDF
Serum-free Media for Therapeutic Cell Manufacturing – Challenges and Innovations
PPTX
Synthetic biology
PPT
Lecture 8 genetic engineering of animal cells
PPTX
Microarray technology and applications
PPTX
HEX structure prediction tool.pptx
PPTX
Single strand conformation polymorphism
PPTX
Co2 incubators
PPTX
Microbiological analysis of milk part II
PPTX
Gel electrophoresis native, denaturing&reducing
PPTX
ICAT Technique in Proteomics
PDF
Use of Rasmol and study of proteins
DOCX
Mother dairy training report
Protein array, types and application
Developing a new probiotic
Fodder yeast production
milk procurement
6 how do we culture cells in the laboratory lecture 6
Serum-free Media for Therapeutic Cell Manufacturing – Challenges and Innovations
Synthetic biology
Lecture 8 genetic engineering of animal cells
Microarray technology and applications
HEX structure prediction tool.pptx
Single strand conformation polymorphism
Co2 incubators
Microbiological analysis of milk part II
Gel electrophoresis native, denaturing&reducing
ICAT Technique in Proteomics
Use of Rasmol and study of proteins
Mother dairy training report
Ad

Similar to Development of novel chemically defined media for CHO cell applications (20)

PDF
Effect of raw materials and production processes on dry powder media quality
PDF
Next Generation Recombinant Protein Manufacturing
PDF
Serum-free Media for Therapeutic Cell Manufacturing – Challenges and Innovations
PDF
Cell Culture Media Filtration – Filter Selection and Sizing
PDF
Platform Techniques for Preformulation Development for Non-Antibody Products
PDF
Undergraduate Thesis - Joel John
PPTX
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
PDF
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...
PPTX
Cell culture, Different type of cell culture media, types of media
PDF
High Throughput Bioreactor Mimetic in Early and Late Stage Process Development
PPTX
Culture media
PPT
Hydrolysate Characterization Technical Presentation Webinar11 2009
PDF
High-throughput Miniaturized Bioreactors for Cell Culture Process Developmen...
PDF
Development of a cutting edge CHO cell culture medium
PDF
Up to Speed: Cell Culture Development. European Biopharmaceutical Review July...
PPTX
3.5 Biotechnology Drugs immunology .pptx
PPTX
Bioengineering theory presentation 2.pptx
PDF
Celonic presentation on VIPS - BPI Boston (Sept 2019)
PDF
Compressed Timelines for Breakthrough Therapies: Impact on Process Characteri...
PDF
Speeding up media design in cell culture - a novel high throughput approach f...
Effect of raw materials and production processes on dry powder media quality
Next Generation Recombinant Protein Manufacturing
Serum-free Media for Therapeutic Cell Manufacturing – Challenges and Innovations
Cell Culture Media Filtration – Filter Selection and Sizing
Platform Techniques for Preformulation Development for Non-Antibody Products
Undergraduate Thesis - Joel John
Reducing Timelines & Increasing Titres by Host Cell Lines with Improved Chara...
Scalability of Cell Culture Processes in Single-use Bioreactors using Differe...
Cell culture, Different type of cell culture media, types of media
High Throughput Bioreactor Mimetic in Early and Late Stage Process Development
Culture media
Hydrolysate Characterization Technical Presentation Webinar11 2009
High-throughput Miniaturized Bioreactors for Cell Culture Process Developmen...
Development of a cutting edge CHO cell culture medium
Up to Speed: Cell Culture Development. European Biopharmaceutical Review July...
3.5 Biotechnology Drugs immunology .pptx
Bioengineering theory presentation 2.pptx
Celonic presentation on VIPS - BPI Boston (Sept 2019)
Compressed Timelines for Breakthrough Therapies: Impact on Process Characteri...
Speeding up media design in cell culture - a novel high throughput approach f...
Ad

More from National Institute of Biologics (20)

PDF
Waters protein therapeutics application proctocols
PDF
Potential aggregation prone regions in biotherapeutics
DOCX
How the biologics landscape is evolving
PDF
Evaluation of antibody drugs quality safety
PDF
Approved m abs_feb_2015
PDF
Translating next generation sequencing to practice
PDF
From biomarkers to diagnostics –the road to success
PDF
Defining your-target-product-profile in-vitro-diagnostic-products
PDF
Accelerating development and approval of targeted cancer therapies
PDF
Canonical structures for the hypervariable regions of immunoglobulins
PDF
Canonical correlation
PDF
Development trends for human monoclonal antibody therapeutics
PDF
Therapeutic fc fusion proteins and peptides as successful alternatives to ant...
PDF
Fc fusion proteins and fc rn - structural insights for longer-lasting and mor...
PDF
Therapeutic antibodies for autoimmunity and inflammation
PDF
Introduction to current and future protein therapeutics - a protein engineeri...
PDF
Pharmaceutical monoclonal antibodies production - guidelines to cell engine...
PDF
Intended use of reference products & who international standards or reference...
PDF
How dissimilarly similar are biosimilars
PDF
Evaluation of similar biotherapeutic products (SBP's) scientific principles ...
Waters protein therapeutics application proctocols
Potential aggregation prone regions in biotherapeutics
How the biologics landscape is evolving
Evaluation of antibody drugs quality safety
Approved m abs_feb_2015
Translating next generation sequencing to practice
From biomarkers to diagnostics –the road to success
Defining your-target-product-profile in-vitro-diagnostic-products
Accelerating development and approval of targeted cancer therapies
Canonical structures for the hypervariable regions of immunoglobulins
Canonical correlation
Development trends for human monoclonal antibody therapeutics
Therapeutic fc fusion proteins and peptides as successful alternatives to ant...
Fc fusion proteins and fc rn - structural insights for longer-lasting and mor...
Therapeutic antibodies for autoimmunity and inflammation
Introduction to current and future protein therapeutics - a protein engineeri...
Pharmaceutical monoclonal antibodies production - guidelines to cell engine...
Intended use of reference products & who international standards or reference...
How dissimilarly similar are biosimilars
Evaluation of similar biotherapeutic products (SBP's) scientific principles ...

Recently uploaded (20)

DOCX
PEADIATRICS NOTES.docx lecture notes for medical students
PPTX
NRPchitwan6ab2802f9.pptxnepalindiaindiaindiapakistan
PDF
focused on the development and application of glycoHILIC, pepHILIC, and comm...
PPTX
NASO ALVEOLAR MOULDNIG IN CLEFT LIP AND PALATE PATIENT
PPTX
CHEM421 - Biochemistry (Chapter 1 - Introduction)
PPTX
Human Reproduction: Anatomy, Physiology & Clinical Insights.pptx
PPTX
Stimulation Protocols for IUI | Dr. Laxmi Shrikhande
PPTX
IMAGING EQUIPMENiiiiìiiiiiTpptxeiuueueur
PPTX
preoerative assessment in anesthesia and critical care medicine
PPTX
MANAGEMENT SNAKE BITE IN THE TROPICALS.pptx
PDF
شيت_عطا_0000000000000000000000000000.pdf
PPTX
obstructive neonatal jaundice.pptx yes it is
PDF
SEMEN PREPARATION TECHNIGUES FOR INTRAUTERINE INSEMINATION.pdf
PPTX
PRESENTACION DE TRAUMA CRANEAL, CAUSAS, CONSEC, ETC.
PPTX
y4d nutrition and diet in pregnancy and postpartum
PPT
Infections Member of Royal College of Physicians.ppt
PPT
MENTAL HEALTH - NOTES.ppt for nursing students
PPT
STD NOTES INTRODUCTION TO COMMUNITY HEALT STRATEGY.ppt
PPTX
surgery guide for USMLE step 2-part 1.pptx
PPTX
ANATOMY OF MEDULLA OBLANGATA AND SYNDROMES.pptx
PEADIATRICS NOTES.docx lecture notes for medical students
NRPchitwan6ab2802f9.pptxnepalindiaindiaindiapakistan
focused on the development and application of glycoHILIC, pepHILIC, and comm...
NASO ALVEOLAR MOULDNIG IN CLEFT LIP AND PALATE PATIENT
CHEM421 - Biochemistry (Chapter 1 - Introduction)
Human Reproduction: Anatomy, Physiology & Clinical Insights.pptx
Stimulation Protocols for IUI | Dr. Laxmi Shrikhande
IMAGING EQUIPMENiiiiìiiiiiTpptxeiuueueur
preoerative assessment in anesthesia and critical care medicine
MANAGEMENT SNAKE BITE IN THE TROPICALS.pptx
شيت_عطا_0000000000000000000000000000.pdf
obstructive neonatal jaundice.pptx yes it is
SEMEN PREPARATION TECHNIGUES FOR INTRAUTERINE INSEMINATION.pdf
PRESENTACION DE TRAUMA CRANEAL, CAUSAS, CONSEC, ETC.
y4d nutrition and diet in pregnancy and postpartum
Infections Member of Royal College of Physicians.ppt
MENTAL HEALTH - NOTES.ppt for nursing students
STD NOTES INTRODUCTION TO COMMUNITY HEALT STRATEGY.ppt
surgery guide for USMLE step 2-part 1.pptx
ANATOMY OF MEDULLA OBLANGATA AND SYNDROMES.pptx

Development of novel chemically defined media for CHO cell applications

  • 1. Development of novel chemically-defined media for CHO cell applications Dr. Dipl-Ing. Jörg von Hagen Head of Process Development & Launch Management Merck Millipore, Darmstadt, Germany Cell Culture World Congress, Munich 2013
  • 2. Presentation Outline 1 2 Lot to Lot Consistency 3 Platform Consistency 4 Media Performance Prediction 5 Powder handling improvements 6 Solubility Toolbox for high performing media 7 2 CHO Cell Media & Feed – Performance evaluation Perspectives 2
  • 3. A Comparison of IgG Production in CVC-200 and Two Competitor Media and Feed Supplements. 3.5 3 80 2.5 60 2 1.5 40 IgG Titer (g/L) Cell Viability (% Viable Cells) 100 1 20 0.5 0 0 0 3 4 5 6 7 8 9 10 11 12 13 14 Elapsed Time (Day) Competitor A Competitor B Cellvento CHO-200 Competitor A Competitor B Cellvento CHO-200 IgG Production in Cellvento CHO-200 was 2-3 fold higher than two competitor products over a 14 day fed batch culture. 3
  • 4. A Comparison of Cell Growth in CVC-200 and Two Competitor Media and Feed Supplements Cell Growth (VCD) - Competitive Evaluation in Fed Batch 14.00 VCD (10e6 c/ml) 12.00 10.00 8.00 6.00 4.00 2.00 0.00 0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 Elapsed Time (Day) Competitor A Competitor B Cellvento CHO-200 Cell growth in Cellvento CHO-200 achieved above 1x107 cells /mL in a 14 day fed batch culture. 4
  • 5. Presentation Outline 1 2 Lot to Lot Consistency 3 Platform Consistency 4 Media Performance Prediction 5 Powder handling improvements 6 Solubility Toolbox for high performing media 7 5 CHO Cell Media & Feed – Performance evaluation Perspectives 5
  • 6. Integral Viable Cell Density (10e6 cell day/ml) Comparison of Average Cell Growth in Batch Culture 25.00 20.00 Lot 006_1 15.00 Lot 006_2 Lot 006_3 10.00 5.00 0.00 3 4 5 6 Elapsed Time (Days) Cell growth in Cellvento CHO-200 was consistent in batch culture across three lots of media 6
  • 7. Comparison of Cell Growth in Fed Batch Culture Three Lots of Feed tested 18,0 16,0 Viable Cell Density (10e6 c/ml) 14,0 12,0 Feed Lot 007_1 10,0 Feed Lot 007_2 8,0 Feed Lot 007_3 6,0 4,0 2,0 0,0 0 5 10 15 Elapsed Time (Day) Cell growth in Cellvento CHO-200 was consistent in fed batch culture across three lots of feed 7
  • 8. Comparison of IgG Production in Fed Batch Culture Comparison of Volumetric Titers Across Three Lots of Feed 2.0 1.8 1.6 1.4 IgG (g/L) 1.2 Feed Lot 007_1 1.0 Feed Lot 007_2 0.8 Feed Lot 007_3 0.6 0.4 0.2 0.0 7 10 Sample Day IgG production in Cellvento CHO-200 was consistent in fed batch culture across three lots of feed 8
  • 11. Reproducibility amino acid content Cellvento CHO 200 media Amino acid concentration (in % of the theoretical value) 120 100 80 Batch 1 Batch 2 60 Batch 3 40 20 0 His 11 Asn Ser Arg Presentation title in footer | 00 Month 0000 Gly Asp Glu Thr Ala Pro Lys Tyr Met Val Ile Leu Phe
  • 12. Presentation Outline 1 2 Lot to Lot Consistency 3 Platform Consistency 4 Media Performance Prediction 5 Powder handling improvements 6 Solubility Toolbox for high performing media 7 12 CHO Cell Media & Feed – Performance evaluation Perspectives 12
  • 13. A Comparison of Cell Growth in Spin Tubes and 3L Benchtop Bioreactors 16 Viable Cell Density (10e6 c/ml) 14 12 10 3L Cellready Bioreactor 8 50 ml Spin Tubes 6 4 2 0 0 2 4 6 8 10 12 14 Elapsed Time (Day) Similar growth performance was achieved with Cellvento CHO-200 in spin tubes and benchtop bioreactors over a 14 day fed batch culture. 13
  • 14. A Comparison of IgG Production in Spin Tubes and 3L Benchtop Bioreactors 1,8 1,6 1,4 IgG (g/L) 1,2 50 ml Spin Tubes 1 3L Cellready Bioreactor 0,8 0,6 0,4 0,2 0 7 10 Sample Day IgG titers averaged 1.5 g/L after 10 days of fed bath culture using Cellvento CHO-200 in spin tubes and benchtop bioreactors. 14
  • 15. Presentation Outline 1 2 Lot to Lot Consistency 3 Platform Consistency 4 Media Performance Prediction 5 Powder handling improvements 6 Solubility Toolbox for high performing media 7 15 CHO Cell Media & Feed – Performance evaluation Perspectives 15
  • 16. NIR - Near Infrared Spectroscopy A fingerprint method for media performance prediction medium performance high performance low performance PCA-Possibility for clustering good and poor performing media batches Measurement conditions Integrating sphere, PbS-detector, diffuse reflexion Instrument: BrukerVector 22/N Number of scans: 16, Resolution: 8 cm-1, Measurement Range: 12000 – 4000 cm-1
  • 17. Principle component analysis (PCA) Correlation of cellular performance and NIR analysis Supplier C-1 Supplier S Supplier C-2 Supplier B Supplier C-3 EMD Millipore Supplier A PCA of DMEM-F12. Analysis by NIR-Spectroscopy (Bruker, Vektor MPA)
  • 18. Quality Testing of Media … …depends on the appropriate test system 25 cumulative PDL 20 Mill Tech 1-1 15 Mill Tech 1-2 Mill Tech 1-3 Mill Tech 2-1 10 Mill Tech 2-2 Mill Tech 2-3 5 0 0 days 3 days 5 days 7 days 10 days 12 days 14 days 17 days Impact of the milling technology on CHO-S cells grown in chemically defined media. No significant differences are observed in the basic cell culture assay analyzing the cumulative population doubling levels (PDL) using different produced mammalian cell culture media.
  • 19. Sensitive Cell Culture Assays … underline differences in cell culture media performance 70 60 plating efficacy (%) 50 40 30 20 10 0 Supplier A Mill Tech 1-1 Mill Tech 1-2 Mill Tech 1-3 Mill Tech 2-1 Mill Tech 2-2 Mill Tech 2-3 Impact of the milling technology on CHO-S plating efficacy in chemically defined media. CHO-S cells were diluted in the corresponding media and analyzed after 2 weeks on plating efficacy.
  • 20. Impact of Processing Technologies Impact of the milling technology on mAb titer 140 130 Titer ( % to internal reference) 120 110 100 90 80 70 60 50 40 30 20 10 0 Supplier A Mill Tech 2 The media were tested in the production of a monoclonal antibody. Titer was measured by Surface Plasmon Resonance Spectroscopy. Red line indicates the minimum achievable titer according to the specifications.
  • 21. Milling Process Impact on final NBE Attribute Impact of the milling technology on critical antibody attributes 35 Critical Peptides (%) 30 25 20 15 10 5 0 Supplier A Mill Tech 2 Final molecules after capture were analyzed by HPLC to determine the amount (%) of critical peptides that are known to be correlated with lower half life of the drug substance in patient serum samples. The amounts are directly linked with the raw material quality and the production process. Red line indicates the max. value given by the authorities. Dotted red line represents the internal specification limit. Range between dotted blue lines show the target space for good media performance.
  • 22. Presentation Outline 1 2 Lot to Lot Consistency 3 Platform Consistency 4 Media Performance Prediction 5 Powder handling improvements 6 Solubility Toolbox for high performing media 7 22 CHO Cell Media & Feed – Performance evaluation Perspectives 22
  • 23. Humidity and impact on powder flowability CDM II DMEM-F12 CDM I After opening the package the first time the CDM II powder is clumpy. The DMEMF12 and CDM I media are opened several times and are free flowing powders.
  • 24. CDM II: particle size distribution CDM II particle size analysis is technically not feasible by air-jet sieving. After 3 min all material gets like chewing gum, whereas for CDM I and DMEM-F12 particle size distribution analysis went without clumping.
  • 25. CDM composition comparison The CDM I and II composition have the following critical hygroscopic ingredients: – Calcium Chloride 2H2O – Choline Chloride – Ferric Nitrate 9 H2O – Ferrous Sulfate 7 H2O – Sodium phosphate, monobasic, monohydrate  the above listed ingredients are present with a concentration in sum of 1.5% in the CDM I and 9.7% in the CDM II formulation.  6.3-fold enrichment of hygroscopic compounds resulted in a final H 2O titer of 4.05% measured by Karl Fischer Titration in the CDM II powder (compared to 1.05 to 1.2 in DMEM-F12 and CDM I.)
  • 26. Humidity effects solubility of DMEM F12 2 – 8 °C 4 fold accelerated (5min real) 6 h / 28 °C / 90 % rH.
  • 27. 17° increase in avalanche angle after DMEM F12 exposure to 90% rH DMEM F12 before and after flowability measurement (3h/25°C at 90% rH)
  • 28. DMEM-F12 compacted R = Rosa = pinkish uncompressed 20KN 30KN 40KN 50KN 60KN
  • 29. DMEM-F12 compacted uncompressed 20KN 30KN 1 mm 1 mm 1 mm 1 mm 1 mm 1 mm 40KN 50KN 60KN 1-3 mm particle sizes
  • 30. Solubility of DMEM F12 powder vs. granules
  • 31. Filterability of Powder vs. Granules of DMEM F12 Compaction Filter Medium (kN) Family Filter Name Filter Pore Size (µm) Vmax (L/m2) Amin (m2) 0 0 SHR 0,1 9 305 0,28 Express SHR-2L 0.5/0.1 20 555 0,29 30 30 Express SHR 0.1 11 221 0,29 Express SHR-2L 0.5/0.1 37 911 0,31 60 Express SHR 0.1 10 596 0,30 60 DMEM F-12 Express Express SHR-2L 0.5/0.1 44 219 0,31 The Amin represents the minimal surface of membrane needed to process 500L within the defined time.
  • 32. Presentation Outline 1 2 Lot to Lot Consistency 3 Platform Consistency 4 Media Performance Prediction 5 Powder handling improvements 6 Solubility Toolbox for high performing media 7 32 CHO Cell Media & Feed – Performance evaluation Perspectives 32
  • 33. Tyrosine solubility in feed with >110 g/L amino acid & vitamin load L-Tyr 1 L-Tyr 2Na 1 mod L-Tyr I mod L-Tyr II 50 g/L @ pH 7.0 +/- 0.2 70
  • 34. 4,5mM 2Na-Tyr CHO-S growth profile comparing L-Tyrosine Disodium salt vs. modified Tyrosine 4,5mM 2Na-P-Tyr Medium 200 180 160 Lebenszellzahl [vc/ml] x10^5 VCD (x105 vc/mL) 0 1 1 1 1 1 1 1 1 2 3 4 5 6 7 1 29,6333333 33,2 11,5333333 24,15 24,6666667 19 16,4666667 4 753,033333 681,6 61,0666667 528,6 462,9 85,2666667 116,266667 5 1264,53333 1218,13333 73,0666667 1318,4 1197,26667 157,4 135,9 6 1541,13333 1470,4 64,8999992 1409,82503 1441,11333 266,206664 117,206667 7 8 988,936665 333,58 1108,24002 548,75 46,4400007 63,1033333 1393,7 1324,422 1578,69001 1502,80333 375,935004 415,776667 78,376667 71,34 0 1,92 2,07 2,49 4,5mM 2Na-Tyr 0,29546573 140 4.5 mM L-Tyr 2Na 4,5mM 2Na-Tyr 120 100 4,5mM 2Na-P-Tyr 4.5 mM mod L-Tyr 4,5mM 2Na-P-Tyr II 80 60 9.0 mM mod L-Tyr 9mM 2Na-P-Tyr II 40 18,33 0,31 20 9mM 2Na-P-Tyr 0 1 3 9 5 7 time (days) time 11 9 11
  • 35. Presentation Outline 1 2 Lot to Lot Consistency 3 Platform Consistency 4 Media Performance Prediction 5 Powder handling improvements 6 Solubility Toolbox for high performing media 7 35 CHO Cell Media & Feed – Performance evaluation Perspectives 35
  • 36. Perspectives in media preparation • The raw material quality is key for optimal media performance on cellular level • Raw material selection • Raw material pre-processing • Novel raw material development • Supply chain • The production process is directly linked with batch to batch consistency and cellular performance • Milling process • Mixing process • Packaging • The combination of raw materials and the production process is mandatory for excellent dry powder media performance Raw material quality Production process Cellular performance